↑ Rising
Business
SELLAS Life Sciences stock soars 240% on positive cancer trial
SELLAS Life Sciences shares surged 240% after its REGAL trial showed promise for a leukemia vaccine, then slid 10% on a $150 million stock offering.
2 trends tracked about this subject — the full history, oldest to newest below.
SELLAS Life Sciences shares surged 240% after its REGAL trial showed promise for a leukemia vaccine, then slid 10% on a $150 million stock offering.
SELLAS Life Sciences' GPS vaccine demonstrated a 41% reduction in death risk and nine-month survival benefit in a pivotal Phase 3 AML trial, sending shares up 220%.